Search
Selected Filter
Displaying 1–10 of 172 research results
-
The treatment focuses on the P23H mutation in the RHO gene, which is the most prevalent variant causing adRP in the US and affects approximately 2,500 people.
-
Allergan and Editas Begin Recruiting for CRISPR/Cas9 Clinical Trial for LCA10
The trial will be the first for a CRISPR/Cas9 therapy administered inside the human body.
-
The Foundation’s Contributions to Genetic Research Published in Peer-Reviewed Journal
The nonprofit has emerged as a driving force in genetic research and treatment development for inherited retinal diseases.
-
SparingVision Gets EU Funding Boost for Development of Cross-Cutting Gene Therapy
A clinical trial for the treatment, designed to preserve cone photoreceptors, is planned in the US and Europe in 2020.
-
The Retina is a Proving Ground for a Broad Range of Neurological Therapies
Retinal research paves the way for new treatments for the entire neurological system.
-
FDA Wins Case against Stem-Cell Clinic that Blinded Patients with Bogus Treatment
A federal court ruled that the FDA has regulatory authority over these stem-cell procedures and the power to halt them.
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Dr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
